Profile

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

30% lower NHS list price vs. NovoRapid® pre-filled pens and cartridges and 15% lower NHS list price vs. NovoRapid® vials2

1:1 initial unit dosing - available in the SoloStar pen, cartridges and vials1*

*When transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended.1

Similar PK/PD profile (T1DM), efficacy, safety and tolerability (T1DM and T2DM)3-4

    Abbreviations:
    EU, European Union; FAQ, frequently asked questions; NHS, National Health Service; PD, pharmacodynamic; PK, pharmacokinetic; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UK, United Kingdom.

    References:

    1. Trurapi SmPC (September 2021)
    2. NHS DM+M: REF-161114. Available at: https://services.nhsbsa.nhs.uk/dmd-browser Date accessed: June 2022
    3. Kapitza C, et al. Diabetes Technol Ther. 2020;22(4):278–284.
    4. Garg SK, et al. Diabetes Technol Ther. 2020;22(2):85–95.

Diabetes Stories

Watch peer-to-peer videos of payors and healthcare professionals sharing best practices of adopting a rapid acting insulin biosimilar.
These videos are related to HCPs sharing their experiences with a different rapid acting insulin biosimilar.

Marcus Jones - Formulary Pharmacist

Length: 03:43

In this video you can learn how Marcus Jones accelerated the adoption of a rapid acting biosimilar insulin in his local region and how he collaborated with clinical teams to make a positive start and switch.

Dr Duncan Browne - Consultant Endocrinologist

Length: 03:32

In this video you can learn why Duncan Browne decided to prescribe a rapid acting insulin biosimilar, how he aligned internally the local service to drive the adoption of this biosimilar in his local region and find out how the patient experience has been with this biosimilar.

Amanda Veall - Diabetes Specialist Nurse

Length: 04:16

In this video you can learn why Amanda Veall decided to prescribe a rapid acting insulin biosimilar, how she collaborated with clinical teams to drive the adoption of this biosimilar in her local region and find out how the patient experience has been with this biosimilar.

Start and Switch

Watch and download resources to support your rapid acting insulin adoption.

Get in touch with the Diabetes Team

MAT-XU-2201545 (v1.0)
Date of Preparation: June 2022

MAT-GB-2105437 (v2.0)
Date of Preparation: August 2022